GT Biopharma, Inc. (GTBP): Nasdaq/NYSE listing notice — GT Biopharma receives Nasdaq extension to Nov 16, 2026 to meet $1 minimum bid price

GT Biopharma, Inc.

Received Nasdaq Staff letter on May 20, 2026 granting 180-day extension until Nov 16, 2026 for minimum bid price compliance.
Previously received initial deficiency notice on Nov 20, 2025; initial 180-day period expired May 19, 2026.
Company meets all other Nasdaq Capital Market initial listing requirements except for minimum bid price.
No assurance of compliance; company will monitor bid price and assess options to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

GT Biopharma, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(H)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(H)

Exact text from the filing

May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-024913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.